Lymph Node Status in Breast Cancer Does Not Predict Tumor Biology

[1] Coates AS(2015)Tailoring therapies: improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 Ann Oncol 26 1533-1546

[2] Winer EP(2016)Selection of optimal adjuvant chemotherapy regimens for human epidermal growth factor receptor 2 (HER2)-negative and adjuvant targeted therapy for her2-positive breast cancers: an American society of clinical oncology guideline adaptation of the cancer care ontario clinical practice guideline J Clin Oncol 34 2416-2427

[3] Goldhirsch A(2015)Optimal systemic therapy for early breast cancer in women: a clinical practice guideline Curr Oncol 22 S67-S81

[4] Gelber RD(2005)Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 1687-1717

[5] Gnant M(2012)Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials Lancet 379 432-444

[6] Piccart-Gebhart M(2006)Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer J Clin Oncol 24 3726-3734

[7] Denduluri N(2010)Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial Lancet Oncol 11 55-65

[8] Somerfield MR(2007)American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer J Clin Oncol 25 5287-5312

[9] Eisen A(2012)Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer J Clin Oncol 30 2218-2226

[10] Holloway JN(2013)Integrating comparative effectiveness design elements and endpoints into a phase III, randomized clinical trial (SWOG S1007) evaluating oncotypeDX-guided management for women with breast cancer involving lymph nodes Contemp Clin Trials 34 1-9

[1] Coates AS(2015)Tailoring therapies: improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 Ann Oncol 26 1533-1546

[2] Winer EP(2016)Selection of optimal adjuvant chemotherapy regimens for human epidermal growth factor receptor 2 (HER2)-negative and adjuvant targeted therapy for her2-positive breast cancers: an American society of clinical oncology guideline adaptation of the cancer care ontario clinical practice guideline J Clin Oncol 34 2416-2427

[3] Goldhirsch A(2015)Optimal systemic therapy for early breast cancer in women: a clinical practice guideline Curr Oncol 22 S67-S81

[4] Gelber RD(2005)Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 1687-1717

[5] Gnant M(2012)Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials Lancet 379 432-444

[6] Piccart-Gebhart M(2006)Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer J Clin Oncol 24 3726-3734

[7] Denduluri N(2010)Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial Lancet Oncol 11 55-65

[8] Somerfield MR(2007)American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer J Clin Oncol 25 5287-5312

[9] Eisen A(2012)Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer J Clin Oncol 30 2218-2226

[10] Holloway JN(2013)Integrating comparative effectiveness design elements and endpoints into a phase III, randomized clinical trial (SWOG S1007) evaluating oncotypeDX-guided management for women with breast cancer involving lymph nodes Contemp Clin Trials 34 1-9